N/A N=110 The Effect of Vitamin D and Exercise on Balance in Postmenopausal Women
Vitamin D Deficiency
Primary: Postural Stability Test (Biodex) Assessed at Baseline — 2.25; 2.30; 2.18; 1.97 score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
Phase 2 N=36 MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)
Pigmented Villonodular Synovitis · PVNS · Giant Cell Tumor of the Tendon Sheath
Primary: Change in Pigmented Villonodular Synovitis (PVNS) Tumor Size — -4222.8; -668.5; -9998.4; -38002.1 mm3
N/A N=61 Muscle Growth Following a Resistance Training Program in Men and Women Consuming Protein Supplements
Skeletal Muscle Growth
Primary: Lean Body Mass Change — 1.5; 1.3 kilogram — p=<0.05
N/A N=184 Loving-Kindness Meditation for PTSD
Posttraumatic Stress Disorder · Depression
Primary: Clinician Administered PTSD Scale (CAPS-5) Score — 25.92; 28.02 units on a scale
N/A N=292 Impact of a Peer Support Program Amongst COPD Patients and Their Caregivers
COPD
Primary: Change in Health-related Quality of Life at 6 Months — -1.78; -0.52 units on a scale — p=0.467
N/A N=15 Acute Effects of a Flutter Device in COPD
Chronic Obstructive Pulmonary Disease
Primary: Airways Resistance (IOS) — 0.63; 0.61; 0.58; 0.68 kPa/L/s — p=<0.05
N/A N=210 Effects of Maternal Interpretation Biases on Child Anxiety and Related Responses
Anxiety Disorders
Primary: Word Sentence Association Paradigm — 0.37; 0.52; 0.27 units on a scale
Phase 2 N=9 Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
Multiple Myeloma
Primary: Number of Phase I Patients Receiving 2.3mg, 3mg, or 4mg MLN9708 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Maximum Tolerated Dose — 0; 0; 0 Participants
Phase 2 N=17 PK/PD Study of U-500 Regular Insulin
Type 2 Diabetes · Insulin Resistance · High Insulin Requirements
Primary: Duration (in Hours) of 20 % Dextrose Infusion Requirement — 11; 16.5 hours
N/A N=72 Treatment to Enhance Cognition in Bipolar Disorder
Bipolar Disorder · Psychosis
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 45.2; 45.5; 47.7; 49.3 T-scores
Phase 3 N=216 The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
Phase 2 N=60 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis
Myasthenia Gravis
Primary: Percent of Subjects Achieving a 50% or Greater Reduction in CS Dose (Prednisone or Equivalent) From Baseline to Week 39 — 60.0; 63.3; 58.6; 60.7 percentage of subjects…
Phase 1 N=14 A Study to Investigate the Relative Bioavailability of Entrectinib Capsule Formulations F1 and F06 Under Fed Conditions in Healthy Participants
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf) of Entrectinib and M5 Metabolite — 44000; 44900; 14400; 15000 nmol*h/L
Phase 2 N=13 TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Participants With Adverse Events — 0; 15; 15 percentage of participants